Symbols / ABVX Stock $114.56 +1.38% ABIVAX Société Anonyme
ABVX (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Ratings
Current target
$114.56
Low
$131.00
High
$176.00
Mean
$155.20
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-24 | main | Barclays | Overweight → Overweight | $148 |
| 2026-03-16 | init | Jefferies | — → Buy | $160 |
| 2026-02-25 | reit | BTIG | Buy → Buy | $150 |
| 2026-02-24 | init | Wedbush | — → Underperform | $110 |
| 2026-01-09 | main | Morgan Stanley | Overweight → Overweight | $145 |
| 2026-01-08 | main | BTIG | Buy → Buy | $150 |
| 2025-12-16 | main | Citizens | Market Outperform → Market Outperform | $131 |
| 2025-11-24 | init | Truist Securities | — → Buy | $140 |
| 2025-11-06 | init | Wolfe Research | — → Outperform | $176 |
| 2025-10-13 | init | Barclays | — → Overweight | $142 |
| 2025-10-10 | main | Guggenheim | Buy → Buy | $150 |
| 2025-10-07 | main | BTIG | Buy → Buy | $120 |
| 2025-09-25 | main | JMP Securities | Market Outperform → Market Outperform | $114 |
| 2025-09-12 | main | Morgan Stanley | Overweight → Overweight | $101 |
| 2025-09-09 | reit | BTIG | Buy → Buy | $112 |
| 2025-07-29 | main | Piper Sandler | Overweight → Overweight | $112 |
| 2025-07-23 | main | Piper Sandler | Overweight → Overweight | $70 |
| 2025-07-23 | main | LifeSci Capital | Outperform → Outperform | $101 |
| 2025-07-23 | up | Morgan Stanley | Equal-Weight → Overweight | $71 |
| 2025-07-23 | main | Guggenheim | Buy → Buy | $101 |
- Abivax (NASDAQ:ABVX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat Sun, 26 Apr 2026 05
- Does Abivax (ENXTPA:ABVX) Still Offer Upside After A 15x One-Year Surge In Price - simplywall.st Sun, 26 Apr 2026 03
- (ABVX) Risk Channels and Responsive Allocation - Stock Traders Daily Sun, 26 Apr 2026 00
- From fatigue to fibrosis, 9 Abivax abstracts are set for DDW - Stock Titan Wed, 22 Apr 2026 20
- ABIVAX Société Anonyme (ABVX) Share Momentum Builds Amid Takeover Speculation and Advancing Therapeutic Programs - Yahoo Finance Mon, 02 Feb 2026 08
- Abivax CEO suggests no urgency for deal-making (ABVX:NASDAQ) - Seeking Alpha ue, 24 Mar 2026 07
- Nasdaq, S&P 500 futures head into Christmas Eve with caution: Why ASTS, DVAX, ABVX, PATH, GOOGL are on traders' radar today - MSN Fri, 24 Apr 2026 18
- ABVX (Abivax SA American Depositary Shares) posts wider than expected Q4 2025 loss, yet stock notches mild gains in today's trading. - Strong Momentum - Cổng thông tin điện tử tỉnh Tây Ninh hu, 23 Apr 2026 10
- Fund Update: New $61.5M $ABVX stock position opened by JPMORGAN CHASE & CO - Quiver Quantitative Wed, 11 Feb 2026 08
- Is Abivax (ABVX) stock breaking trend structure | Q4 2025: Earnings Underperform - Guidance Update - Cổng thông tin điện tử tỉnh Lào Cai hu, 23 Apr 2026 07
- Abivax shareholders can now review May 11 Paris meeting documents - Stock Titan Mon, 20 Apr 2026 20
- Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat Fri, 24 Apr 2026 07
- Abivax: Obefazimod’s Strategic Scarcity Drives Optionality (Maintaining Buy) (NASDAQ:ABVX) - Seeking Alpha Wed, 01 Apr 2026 07
- Is It Too Late To Reassess Abivax (ENXTPA:ABVX) After Multi Year Share Price Surge? - Yahoo Finance Mon, 23 Feb 2026 08
- Abivax shares rise as investors revisit recent ECCO updates ahead of 2026 trial milestones - Quiver Quantitative hu, 12 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
—
|
—
|
—
|
50.76
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
—
|
50.53
|
| Gross Profit |
|
—
|
—
|
—
|
-50.76
|
| Operating Expense |
|
246.06
+42.24%
|
172.98
+35.80%
|
127.38
+148.76%
|
51.20
|
| Research And Development |
|
177.76
+21.31%
|
146.53
+42.02%
|
103.18
+113.64%
|
48.30
|
| Selling General And Administration |
|
72.86
+87.31%
|
38.90
+34.97%
|
28.82
+284.65%
|
7.49
|
| Selling And Marketing Expense |
|
0.22
-75.97%
|
0.93
+31.45%
|
0.71
|
0.00
|
| General And Administrative Expense |
|
72.64
+91.32%
|
37.97
+35.05%
|
28.11
+275.19%
|
7.49
|
| Salaries And Wages |
|
56.16
+158.14%
|
21.76
+46.86%
|
14.81
+955.95%
|
1.40
|
| Other Gand A |
|
16.48
+1.64%
|
16.21
+21.91%
|
13.30
+118.36%
|
6.09
|
| Other Operating Expenses |
|
-4.57
+63.29%
|
-12.45
-169.38%
|
-4.62
-0.83%
|
-4.58
|
| Total Expenses |
|
246.06
+42.24%
|
172.98
+35.80%
|
127.38
+148.76%
|
51.20
|
| Operating Income |
|
-246.06
-42.24%
|
-172.98
-35.80%
|
-127.38
-148.76%
|
-51.20
|
| Total Operating Income As Reported |
|
-246.06
-42.24%
|
-172.98
-35.81%
|
-127.38
-96.46%
|
-64.84
|
| EBITDA |
|
-300.70
-84.81%
|
-162.71
-22.15%
|
-133.21
-149.85%
|
-53.31
|
| Normalized EBITDA |
|
-268.99
-62.64%
|
-165.38
-35.17%
|
-122.36
-149.45%
|
-49.05
|
| Reconciled Depreciation |
|
1.07
-2.55%
|
1.10
+55.59%
|
0.71
+45.77%
|
0.48
|
| EBIT |
|
-301.77
-84.22%
|
-163.81
-22.33%
|
-133.91
-148.91%
|
-53.80
|
| Total Unusual Items |
|
-31.71
-1285.90%
|
2.67
+124.64%
|
-10.85
-154.38%
|
-4.27
|
| Total Unusual Items Excluding Goodwill |
|
-31.71
-1285.90%
|
2.67
+124.64%
|
-10.85
-154.38%
|
-4.27
|
| Special Income Charges |
|
-3.84
|
0.00
+100.00%
|
-3.24
+76.24%
|
-13.63
|
| Other Special Charges |
|
3.84
|
—
|
3.24
-76.65%
|
13.87
|
| Impairment Of Capital Assets |
|
—
|
0.00
|
0.00
-100.00%
|
13.63
|
| Restructuring And Mergern Acquisition |
|
—
|
1.37
+142.75%
|
-3.20
-121.16%
|
-1.45
|
| Net Income |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Pretax Income |
|
-330.25
-87.39%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Net Non Operating Interest Income Expense |
|
-52.49
-784.94%
|
-5.93
+37.63%
|
-9.51
-80.42%
|
-5.27
|
| Interest Expense Non Operating |
|
28.48
+129.12%
|
12.43
-10.09%
|
13.83
+99.22%
|
6.94
|
| Net Interest Income |
|
-52.49
-784.94%
|
-5.93
+37.63%
|
-9.51
-80.42%
|
-5.27
|
| Interest Expense |
|
28.48
+129.12%
|
12.43
-10.09%
|
13.83
+99.22%
|
6.94
|
| Interest Income Non Operating |
|
5.75
-35.76%
|
8.96
+222.97%
|
2.77
|
0.00
|
| Interest Income |
|
5.75
-35.76%
|
8.96
+222.97%
|
2.77
|
0.00
|
| Other Income Expense |
|
-31.71
-1285.90%
|
2.67
+124.64%
|
-10.85
-154.38%
|
-4.27
|
| Other Non Operating Income Expenses |
|
—
|
-1.37
-142.75%
|
3.20
+121.16%
|
1.45
|
| Gain On Sale Of Security |
|
-27.87
-1142.37%
|
2.67
+135.12%
|
-7.61
-181.28%
|
9.37
|
| Tax Provision |
|
5.85
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
-7.93
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Net Income From Continuing Operation Net Minority Interest |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Net Income From Continuing And Discontinued Operation |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Net Income Continuous Operations |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Normalized Income |
|
-312.32
-74.56%
|
-178.92
-30.70%
|
-136.89
-142.39%
|
-56.47
|
| Net Income Common Stockholders |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
0.00
|
0.00
|
| Diluted EPS |
|
—
|
-2.78
+18.91%
|
-3.43
-7.86%
|
-3.18
|
| Basic EPS |
|
—
|
-2.78
+18.91%
|
-3.43
-7.86%
|
-3.18
|
| Basic Average Shares |
|
—
|
63.35
+47.09%
|
43.07
+125.57%
|
19.09
|
| Diluted Average Shares |
|
—
|
63.35
+47.09%
|
43.07
+125.57%
|
19.09
|
| Diluted NI Availto Com Stockholders |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
—
|
—
|
0.07
|
| Depreciation And Amortization In Income Statement |
|
—
|
—
|
—
|
0.07
|
| Depreciation Income Statement |
|
—
|
—
|
—
|
0.07
|
| Other Taxes |
|
—
|
—
|
—
|
0.04
|
| Rent And Landing Fees |
|
—
|
—
|
—
|
1.05
|
| Rent Expense Supplemental |
|
—
|
—
|
—
|
1.05
|
| Total Other Finance Cost |
|
29.76
+1111.60%
|
2.46
+259.17%
|
-1.54
+7.55%
|
-1.67
|
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Assets |
|
327.06
+332.94%
|
75.54
|
—
|
| Current Assets |
|
285.97
+690.39%
|
36.18
|
—
|
| Cash Cash Equivalents And Short Term Investments |
|
260.99
+868.43%
|
26.95
|
—
|
| Cash And Cash Equivalents |
|
251.94
+834.85%
|
26.95
|
—
|
| Cash Equivalents |
|
18.11
-32.81%
|
26.94
|
—
|
| Cash Financial |
|
233.84
+3897183.33%
|
0.01
|
—
|
| Other Short Term Investments |
|
9.05
|
0.00
|
—
|
| Receivables |
|
19.10
+129.67%
|
8.32
|
—
|
| Accounts Receivable |
|
—
|
—
|
1.47
|
| Other Receivables |
|
0.06
-76.38%
|
0.25
+6250.00%
|
0.00
|
| Taxes Receivable |
|
19.04
+136.16%
|
8.06
|
—
|
| Inventory |
|
—
|
—
|
4.00
|
| Work In Process |
|
—
|
—
|
4.00
|
| Prepaid Assets |
|
5.88
+542.84%
|
0.92
|
—
|
| Current Deferred Assets |
|
5.75
+527.98%
|
0.92
+26.91%
|
0.72
|
| Other Current Assets |
|
-0.00
|
—
|
-0.00
|
| Total Non Current Assets |
|
41.09
+4.39%
|
39.36
|
—
|
| Net PPE |
|
0.88
-44.91%
|
1.59
|
—
|
| Gross PPE |
|
2.37
-1.42%
|
2.40
|
—
|
| Accumulated Depreciation |
|
-1.49
-84.28%
|
-0.81
|
—
|
| Properties |
|
0.00
|
0.00
|
—
|
| Buildings And Improvements |
|
1.35
-16.81%
|
1.62
|
—
|
| Machinery Furniture Equipment |
|
0.51
+46.53%
|
0.35
|
—
|
| Construction In Progress |
|
—
|
0.07
+570.00%
|
0.01
|
| Other Properties |
|
0.51
+17.66%
|
0.44
|
—
|
| Goodwill And Other Intangible Assets |
|
25.02
-0.01%
|
25.03
|
—
|
| Goodwill |
|
18.42
+0.00%
|
18.42
|
—
|
| Other Intangible Assets |
|
6.60
-0.05%
|
6.61
|
—
|
| Investments And Advances |
|
0.12
|
0.00
|
—
|
| Non Current Deferred Assets |
|
2.32
+123.72%
|
1.04
|
0.00
|
| Non Current Prepaid Assets |
|
15.07
+28.67%
|
11.71
|
—
|
| Other Non Current Assets |
|
2.32
+123.94%
|
1.04
|
—
|
| Total Liabilities Net Minority Interest |
|
131.05
+91.72%
|
68.36
|
—
|
| Current Liabilities |
|
88.11
+71.22%
|
51.46
|
—
|
| Payables And Accrued Expenses |
|
53.29
+199.83%
|
17.77
|
—
|
| Payables |
|
53.29
+199.83%
|
17.77
|
—
|
| Accounts Payable |
|
47.22
+205.14%
|
15.47
|
—
|
| Other Payable |
|
3.69
+174.04%
|
1.35
+14.24%
|
1.18
|
| Current Accrued Expenses |
|
—
|
0.66
-56.25%
|
1.50
|
| Employee Benefits |
|
0.63
+3.11%
|
0.61
|
—
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
1.16
+114.68%
|
0.54
|
| Total Tax Payable |
|
6.07
+164.04%
|
2.30
|
—
|
| Current Debt And Capital Lease Obligation |
|
31.26
+4.08%
|
30.03
|
—
|
| Current Debt |
|
30.88
+4.72%
|
29.49
+193.07%
|
10.06
|
| Other Current Borrowings |
|
30.88
+4.72%
|
29.49
+193.07%
|
10.06
|
| Current Capital Lease Obligation |
|
0.38
-30.46%
|
0.55
|
—
|
| Current Deferred Liabilities |
|
0.05
-60.90%
|
0.13
|
—
|
| Current Deferred Revenue |
|
0.05
-60.90%
|
0.13
|
—
|
| Other Current Liabilities |
|
3.51
-0.34%
|
3.52
+216.64%
|
1.11
|
| Total Non Current Liabilities Net Minority Interest |
|
42.94
+154.19%
|
16.89
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
26.78
+193.46%
|
9.13
|
—
|
| Long Term Debt |
|
26.62
+221.24%
|
8.29
-76.05%
|
34.61
|
| Long Term Capital Lease Obligation |
|
0.16
-80.93%
|
0.84
|
—
|
| Long Term Provisions |
|
0.03
-25.00%
|
0.04
|
—
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
0.63
+3.11%
|
0.61
|
—
|
| Non Current Deferred Liabilities |
|
0.00
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
0.00
|
—
|
—
|
| Other Non Current Liabilities |
|
15.49
+136.59%
|
6.55
|
—
|
| Stockholders Equity |
|
196.01
+2626.53%
|
7.19
|
—
|
| Common Stock Equity |
|
196.01
+2626.53%
|
7.19
|
—
|
| Capital Stock |
|
0.63
+182.06%
|
0.22
|
—
|
| Common Stock |
|
0.63
+182.06%
|
0.22
|
—
|
| Share Issued |
|
62.93
+182.18%
|
22.30
|
—
|
| Ordinary Shares Number |
|
62.92
+182.13%
|
22.30
|
—
|
| Treasury Shares Number |
|
0.01
-5.51%
|
0.01
+39.53%
|
0.01
|
| Additional Paid In Capital |
|
478.22
+217.80%
|
150.48
|
—
|
| Retained Earnings |
|
-282.95
-97.16%
|
-143.51
|
—
|
| Gains Losses Not Affecting Retained Earnings |
|
0.11
|
0.00
|
—
|
| Total Equity Gross Minority Interest |
|
196.01
+2626.53%
|
7.19
|
—
|
| Total Capitalization |
|
222.63
+1338.48%
|
15.48
|
—
|
| Working Capital |
|
197.86
+1394.71%
|
-15.28
|
—
|
| Invested Capital |
|
253.51
+463.79%
|
44.97
|
—
|
| Total Debt |
|
58.04
+48.22%
|
39.16
|
—
|
| Net Debt |
|
—
|
10.83
|
—
|
| Capital Lease Obligations |
|
0.54
-61.05%
|
1.38
|
—
|
| Net Tangible Assets |
|
170.99
+1058.61%
|
-17.84
|
—
|
| Tangible Book Value |
|
170.99
+1058.61%
|
-17.84
|
—
|
| Available For Sale Securities |
|
0.12
+61.04%
|
0.08
-65.00%
|
0.22
|
| Current Provisions |
|
—
|
—
|
0.16
|
| Derivative Product Liabilities |
|
0.00
-100.00%
|
0.57
|
—
|
| Foreign Currency Translation Adjustments |
|
0.11
|
0.00
|
—
|
| Interest Payable |
|
—
|
0.66
+0.46%
|
0.65
|
| Investmentin Financial Assets |
|
0.12
|
0.00
|
—
|
| Non Current Note Receivables |
|
—
|
1.24
-54.85%
|
2.74
|
| Notes Receivable |
|
0.06
-76.38%
|
0.25
|
—
|
| Other Equity Interest |
|
—
|
6.82
-0.26%
|
6.84
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-161.13
-4.58%
|
-154.07
-58.62%
|
-97.13
-80.08%
|
-53.94
|
| Cash Flow From Continuing Operating Activities |
|
-161.13
-4.58%
|
-154.07
-58.63%
|
-97.13
-80.09%
|
-53.93
|
| Net Income From Continuing Operations |
|
-336.10
-90.70%
|
-176.24
-19.29%
|
-147.74
-143.23%
|
-60.74
|
| Depreciation Amortization Depletion |
|
1.07
-2.55%
|
1.10
+55.59%
|
0.71
+45.77%
|
0.48
|
| Depreciation |
|
—
|
—
|
0.71
|
—
|
| Amortization Cash Flow |
|
—
|
—
|
0.00
-100.00%
|
0.31
|
| Depreciation And Amortization |
|
1.07
-2.55%
|
1.10
+55.59%
|
0.71
+45.77%
|
0.48
|
| Amortization Of Intangibles |
|
—
|
—
|
0.00
-100.00%
|
0.31
|
| Other Non Cash Items |
|
22.03
+1174.26%
|
-2.05
-109.52%
|
21.54
+224.66%
|
6.63
|
| Pension And Employee Benefit Expense |
|
-0.07
-187.84%
|
0.07
-32.11%
|
0.11
-23.78%
|
0.14
|
| Stock Based Compensation |
|
35.40
+75.02%
|
20.22
+147.27%
|
8.18
+802.66%
|
-1.16
|
| Provisionand Write Offof Assets |
|
44.71
|
0.00
|
0.00
|
—
|
| Asset Impairment Charge |
|
—
|
0.00
|
0.00
-100.00%
|
13.63
|
| Deferred Tax |
|
5.85
|
0.00
|
0.00
|
—
|
| Deferred Income Tax |
|
5.85
|
0.00
|
0.00
|
—
|
| Operating Gains Losses |
|
62.27
+4124.22%
|
1.47
+236.10%
|
-1.08
+89.96%
|
-10.78
|
| Gain Loss On Investment Securities |
|
62.33
+4352.14%
|
1.40
+217.45%
|
-1.19
+89.09%
|
-10.93
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
—
|
5.57
|
0.00
|
| Change In Working Capital |
|
3.65
+156.64%
|
1.42
-93.31%
|
21.27
+1162.24%
|
-2.00
|
| Change In Receivables |
|
7.04
+53.39%
|
4.59
+132.26%
|
-14.23
-4661.22%
|
0.31
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
—
|
| Change In Payables And Accrued Expense |
|
-4.10
+16.85%
|
-4.93
-113.86%
|
35.58
+1654.98%
|
-2.29
|
| Change In Payable |
|
-4.10
+16.85%
|
-4.93
-113.86%
|
35.58
+1654.98%
|
-2.29
|
| Change In Account Payable |
|
-6.21
-80.31%
|
-3.44
-110.84%
|
31.76
+1429.86%
|
-2.39
|
| Change In Other Working Capital |
|
0.71
-59.73%
|
1.76
+2276.54%
|
-0.08
-211.54%
|
-0.03
|
| Change In Other Current Assets |
|
—
|
—
|
3.74
+11787.50%
|
-0.03
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
—
|
| Investing Cash Flow |
|
-8.19
-151.98%
|
15.76
+294.71%
|
-8.10
+32.69%
|
-12.03
|
| Cash Flow From Continuing Investing Activities |
|
-8.19
-151.98%
|
15.76
+294.73%
|
-8.10
+32.69%
|
-12.03
|
| Net PPE Purchase And Sale |
|
-0.14
+77.81%
|
-0.64
-141.51%
|
-0.27
+7.99%
|
-0.29
|
| Purchase Of PPE |
|
-0.14
+77.81%
|
-0.64
-141.51%
|
-0.27
+7.99%
|
-0.29
|
| Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Capital Expenditure |
|
-0.14
+77.92%
|
-0.64
-142.64%
|
-0.27
+17.96%
|
-0.32
|
| Net Investment Purchase And Sale |
|
—
|
—
|
-8.61
-1731.91%
|
-0.47
|
| Purchase Of Investment |
|
—
|
—
|
-9.35
-1889.57%
|
-0.47
|
| Sale Of Investment |
|
—
|
—
|
0.74
+239.91%
|
0.22
|
| Net Business Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-2.91
|
| Purchase Of Business |
|
—
|
0.00
|
0.00
+100.00%
|
-2.91
|
| Net Intangibles Purchase And Sale |
|
0.00
+100.00%
|
-0.00
|
0.00
+100.00%
|
-0.04
|
| Purchase Of Intangibles |
|
0.00
+100.00%
|
-0.00
|
0.00
+100.00%
|
-0.04
|
| Net Other Investing Changes |
|
-13.58
-265.08%
|
8.23
+180.42%
|
-10.23
-16.13%
|
-8.81
|
| Financing Cash Flow |
|
547.31
+1840.32%
|
28.21
-91.59%
|
335.29
+940.92%
|
32.21
|
| Cash Flow From Continuing Financing Activities |
|
547.31
+1840.32%
|
28.21
-91.59%
|
335.29
+940.88%
|
32.21
|
| Net Issuance Payments Of Debt |
|
-59.53
-258.81%
|
37.49
+145.99%
|
15.24
+256.93%
|
-9.71
|
| Issuance Of Debt |
|
0.00
-100.00%
|
47.94
-14.14%
|
55.84
|
0.00
|
| Repayment Of Debt |
|
-59.53
-469.26%
|
-10.46
+74.24%
|
-40.60
-318.10%
|
-9.71
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
47.94
-14.14%
|
55.84
|
0.00
|
| Long Term Debt Payments |
|
-59.53
-469.26%
|
-10.46
+74.24%
|
-40.60
-318.10%
|
-9.71
|
| Net Long Term Debt Issuance |
|
-59.53
-258.81%
|
37.49
+145.99%
|
15.24
+256.93%
|
-9.71
|
| Net Common Stock Issuance |
|
648.12
+149237.33%
|
0.43
-99.88%
|
353.39
+662.04%
|
46.37
|
| Cash Dividends Paid |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
5.82
|
0.00
|
0.00
-100.00%
|
0.00
|
| Net Other Financing Charges |
|
-40.61
-1913.58%
|
-2.02
+92.81%
|
-28.06
-6320.37%
|
-0.44
|
| Changes In Cash |
|
382.71
+447.60%
|
-110.10
-147.86%
|
230.06
+781.65%
|
-33.75
|
| Effect Of Exchange Rate Changes |
|
-10.25
-530.35%
|
2.38
+146.96%
|
-5.07
|
0.00
|
| Beginning Cash Position |
|
144.22
-42.76%
|
251.94
+834.85%
|
26.95
-55.60%
|
60.70
|
| End Cash Position |
|
516.68
+258.26%
|
144.22
-42.76%
|
251.94
+834.85%
|
26.95
|
| Free Cash Flow |
|
-161.27
-4.24%
|
-154.72
-58.85%
|
-97.39
-79.50%
|
-54.26
|
| Change In Income Tax Payable |
|
2.11
+241.90%
|
-1.49
-138.92%
|
3.82
+3721.00%
|
0.10
|
| Change In Tax Payable |
|
2.11
+241.90%
|
-1.49
-138.92%
|
3.82
+3721.00%
|
0.10
|
| Common Stock Issuance |
|
648.12
+149237.33%
|
0.43
-99.88%
|
353.39
+662.04%
|
46.37
|
| Interest Paid CFF |
|
-6.49
+15.67%
|
-7.70
-45.79%
|
-5.28
-31.48%
|
-4.01
|
| Interest Paid CFO |
|
—
|
—
|
—
|
—
|
| Interest Received CFI |
|
5.53
-32.38%
|
8.18
+240.75%
|
2.40
+12531.58%
|
0.02
|
| Interest Received CFO |
|
—
|
—
|
—
|
—
|
| Issuance Of Capital Stock |
|
648.12
+149237.33%
|
0.43
-99.88%
|
353.39
+662.04%
|
46.37
|
| Other Cash Adjustment Inside Changein Cash |
|
4.73
|
0.00
|
0.00
|
—
|
| Other Cash Adjustment Outside Changein Cash |
|
—
|
—
|
-0.00
+66.67%
|
-0.00
|
| Taxes Refund Paid |
|
—
|
—
|
—
|
—
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|